AR and neoplasm: Clinically, ERG+/PTEN+ tumours are known to be sensitive to AR-targeted therapies, such as androgen deprivation therapy (ADT), abiraterone, and enzalutamide, which form the keystone of treatment for this tumour molecular subtype (103).